320 related articles for article (PubMed ID: 32311699)
1. Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes.
Park M; Jung HL; Shim YJ; Kim HS; Yoon HS; Park SK; Cheuh HW; Lee MJ; Lee JM; Park ES; Lee JH; Lim YJ; Choi YB
Pediatr Res; 2020 Nov; 88(5):749-755. PubMed ID: 32311699
[TBL] [Abstract][Full Text] [Related]
2. Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?
Babiak-Choroszczak L; Giżewska-Kacprzak K; Gawrych E; Fischer K; Walecka A; Puchalska-Niedbał L; Rajewska-Majchrzak J; Bagłaj M
Adv Clin Exp Med; 2018 May; 27(5):703-710. PubMed ID: 29790692
[TBL] [Abstract][Full Text] [Related]
3. [Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type].
Yujuan T; Shaoquan C; Zaizhong Z; Shuming C; Guoliang H; Lie W
Zhonghua Zheng Xing Wai Ke Za Zhi; 2015 Jul; 31(4):268-73. PubMed ID: 26665926
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol.
Şen HS; Yalçın B; Canpınar H; Ocak S; Akyüz C
Turk J Pediatr; 2020; 62(6):979-985. PubMed ID: 33372436
[TBL] [Abstract][Full Text] [Related]
5. Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy.
Chen XD; Ma G; Huang JL; Chen H; Jin YB; Ye XX; Hu XJ; Lin XX
Pediatr Dermatol; 2013; 30(5):549-53. PubMed ID: 23909679
[TBL] [Abstract][Full Text] [Related]
6. [Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma].
Yuan WL; Wang XK
Shanghai Kou Qiang Yi Xue; 2022 Aug; 31(4):400-405. PubMed ID: 36710554
[TBL] [Abstract][Full Text] [Related]
7. Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor.
Ozeki M; Nozawa A; Hori T; Kanda K; Kimura T; Kawamoto N; Fukao T
Pediatr Int; 2016 Nov; 58(11):1130-1135. PubMed ID: 26991797
[TBL] [Abstract][Full Text] [Related]
8. Tissue and serum mRNA profile of MMPs-2/9 as a potential novel biomarker for the most individual approach in infantile hemangiomas and cancer disease.
Taran K; Wnęk A; Kobos J; Andrzejewska E; Przewratil P
Immunobiology; 2017 Nov; 222(11):1035-1042. PubMed ID: 28601470
[TBL] [Abstract][Full Text] [Related]
9. Serum apelin as a potential biomarker for infantile hemangiomas.
Chen Q; Zhang Y; Ni S; Yang L; Li J; Yuan X; Chen M; Liu J; Luo X; Xie Y; Wang H
Pediatr Blood Cancer; 2024 Jul; 71(7):e30989. PubMed ID: 38602300
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma.
Aydin Köker S; Kömüroğlu AU; Köksoy AY; Şiraz ÜG; Tekin E; Köker A
Arch Pediatr; 2021 May; 28(4):296-300. PubMed ID: 33715934
[TBL] [Abstract][Full Text] [Related]
11. Predictors of poor response to oral propranolol in infantile hemangiomas.
Hali F; Moubine I; Berrami H; Serhier Z; Othmani MB; Chiheb S
Arch Pediatr; 2023 Oct; 30(7):455-457. PubMed ID: 37394367
[TBL] [Abstract][Full Text] [Related]
12. Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol.
Sondhi V; Patnaik SK
J Pediatr Hematol Oncol; 2013 Oct; 35(7):493-9. PubMed ID: 23929318
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma.
Makkeyah SM; Elseedawy ME; Abdel-Kader HM; Mokhtar GM; Ragab IA
Pediatr Hematol Oncol; 2022 Apr; 39(3):215-224. PubMed ID: 34477031
[TBL] [Abstract][Full Text] [Related]
14. Oral propranolol: an effective, safe treatment for infantile hemangiomas.
Zaher H; Rasheed H; Hegazy RA; Hegazy RA; Abdelhalim DM; Gawdat HI
Eur J Dermatol; 2011; 21(4):558-63. PubMed ID: 21697036
[TBL] [Abstract][Full Text] [Related]
15. Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas.
MacIsaac ZM; Nayar HS; Gehris R; Mehta D; Geisler S; Grunwaldt LJ
J Craniofac Surg; 2016 Jan; 27(1):159-62. PubMed ID: 26674892
[TBL] [Abstract][Full Text] [Related]
16. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas.
Thaivalappil S; Bauman N; Saieg A; Movius E; Brown KJ; Preciado D
JAMA Otolaryngol Head Neck Surg; 2013 Oct; 139(10):1026-31. PubMed ID: 24135743
[TBL] [Abstract][Full Text] [Related]
17. Circulating Levels of Vascular Endothelial Growth Factor and Basic Fibroblastic Growth Factor in Infantile Hemangioma Versus Vascular Malformations.
El-Raggal NM; El-Farrash RA; Saad AA; Attia EAS; Saafan HA; Shaaban IS
Clin Appl Thromb Hemost; 2018 May; 24(4):663-668. PubMed ID: 28595487
[TBL] [Abstract][Full Text] [Related]
18. Propranolol therapy for infantile hemangioma: our experience.
Zhang L; Wu HW; Yuan W; Zheng JW
Drug Des Devel Ther; 2017; 11():1401-1408. PubMed ID: 28507428
[TBL] [Abstract][Full Text] [Related]
19. Propranolol treatment in life-threatening airway hemangiomas: a case series and review of literature.
Broeks IJ; Hermans DJ; Dassel AC; van der Vleuten CJ; van Beynum IM
Int J Pediatr Otorhinolaryngol; 2013 Nov; 77(11):1791-800. PubMed ID: 24074695
[TBL] [Abstract][Full Text] [Related]
20. Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment.
Przewratil P; Kobos J; Wnęk A; Szemraj J; Wyrzykowski D; Chrzanowska B; Andrzejewska E; Taran K
Immunol Lett; 2016 Jul; 175():44-9. PubMed ID: 27178307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
